Dr. Salerno Discusses Hypofractionation for Early Breast Cancer
Kilian Salerno, MD, director of Breast Radiation and Soft Tissue/Melanoma Radiation, Roswell Park Cancer Institute, discusses hypofractionated radiotherapy for the treatment of patients with early-stage breast cancer.
Kilian Salerno, MD, director of Breast Radiation and Soft Tissue/Melanoma Radiation, Roswell Park Cancer Institute, discusses hypofractionated radiotherapy for the treatment of patients with early-stage breast cancer. Salerno addressed the topic of NCCN guideline updates in breast cancer at the 2016 NCCN Annual Conference.
There is compelling evidence that hypofractionation to the whole breast elicits equivalent, if not better, outcomes for women compared with the conventional regimen. Data from two large studies showed that in addition to outcomes, cosmetic outcomes were also the same, if not better, and toxicity was more tolerable for patients.
Salerno says the tweaking of the guidelines to state that hypofractionation is “preferred” is an important change. She says she hopes that it will lead to greater adoption throughout the United States.
<<<
